Ubs Group Ag Cassava Sciences Inc Put Options Transaction History

Ubs Group Ag

4 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2022 Aug 10, 2022	BUY	$17.22 - $38.47 $6,888 - $15,388	400 Added 2.12%	19,300 $543,000
Q1 2022 May 16, 2022	SELL	$32.6 - $53.05 $211,900 - $344,825	-6,500 Reduced 25.59%	18,900 $702,000
Q4 2021 Feb 14, 2022	SELL	$36.77 - $90.91 $661,860 - $1.64 Million	-18,000 Reduced 41.47%	25,400 $1.11 Million
Q3 2021 Nov 15, 2021	BUY	$41.79 - $135.3 $1.81 Million - $5.87 Million	43,400 New	43,400 $2.69 Million

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $100M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.